CLINICAL_TRIALS
trial_result
· 2011-01-17
Clinical Trial Update: Long-Term, Open Label Atomoxetine Study [Phase 3]
Summary
Long-term, open-label Phase 3 study of atomoxetine in attention-deficit/hyperactivity disorder completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2011-01-17